



DENNIS BAILEY

DVM, DACVIM (Oncology)

Board-Certified Veterinary Oncologist
Chief Medical Officer – Paramus

Publications

Bailey D, Erb H, Williams L, Ruslander D, Hauck M. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. *J Vet Intern Med* 2003;17:199-205.

Bailey DB, Rassnick KM, Erb HN, Dykes NL, Hoopes PJ, Page RL. Effect of glomerular filtration rate on carboplatin clearance and myelotoxicity in tumor-bearing cats. *Am J Vet Res* 2004;11:1502-1507

McEntee MC, Rassnick KM, Bailey DB, Balkman CB, Zgola MM, Page RL. Phase I evaluation of oral docetaxel and cyclosporine A in tumor-bearing cats. *J Vet Intern Med* 2006;20:1370-1375.

Flory A, Rassnick K, Al-Sarraf R, Bailey D, Balkman C, Kiselow M, Autio K. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. *J Vet Intern Med* 2008;22:164-171.

5. Bailey DB, Rassnick KM, Kristal O, Chretin JD, Balkman CE. Phase I escalation of single agent vinblastine in dogs. *J Vet Intern Med*. 2008;22:1397-1402.

Rassnick KM, Bailey DB, Flory AB, Balkman CE, Kiselow MA, Intile JI, Autio K. Efficacy of vinblastine for treatment of canine mast cell tumors. *J Vet Intern Med*. 2008;22:1390-1396.

Bailey DB, Rassnick KM, Dykes NL, Pendyala L. Phase I evaluation of carboplatin in cats using a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and patient glomerular filtration rate. *Am J Vet Res*. 2009;70:770-776.

Rassnick KM, Moore AS, Collister KE, Northrup NC, Kristal O, Chretin JD, Bailey DB. Efficacy of combination chemotherapy for the treatment of gastrointestinal lymphoma in dogs. *J Vet Intern Med* 2009;23:317-322.

Intile JL, Rassnick KM, Bailey DB, Al-Sarraf R, Chretin JD, Balkman CE, Flory AB, Kiselow MA, Wakschlag JJ. Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs. *Vet Comp Oncol* 2009;7:69-77.

Publications (cont.)

1Bailey DB, Rassnick KM, Prey JD, Dykes NL. Evaluation of serum iohexol clearance for use in predicting carboplatin clearance in cats. *Am J Vet Res* 2009;70:1135-1140.

Rassnick KM, Moore AS, Russell DS, Northrup NC, Kristal O, Bailey DB, Flory AF, Kiselow MA, Intile JL. Phase II, open-label trial of single agent CCNU in dogs with previously untreated histiocytic sarcoma. *J Vet Intern Med* 2010;24:1528-1531.

Regan RC, Rassnick KM, Balkman CE, Bailey DB, McDonough SP. Comparison of first-opinion and second-opinion histopathology from dogs and cats with cancer: 430 cases (2001-2008). *Vet Comp Oncol* 2010;8:1-10.

Rassnick KM, Al-Sarraf R, Bailey DB, Chretien JD, Phillips B, Zwhalen CH. Phase II open label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs. *Vet Comp Oncol* 2010;8:103-111.

Rassnick KM, Bailey DB, Russell DS, Flory AB, Kiselow MA, Intile JL, Malone EK, Balkman CE, Barnard SM. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic, or nonresectable mast cell tumors. *Vet Comp Oncol* 2010;8:138-152.

Rassnick KM, Bailey DB, Malone EK, Intile JL, Kiselow MA, Flory AF, Barlow LL, Balkman CE, Barnard SM, Waite AH. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs. *Vet Comp Oncol* 2010;8:243-253.

Rassnick KM, Muindi JR, Johnson CS, Bailey DB, Trump DL. Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. *Cancer Chemother Pharmacol* 2011;67:165-171.

Malone EK, Rassnick KM, Bailey DB, Kiselow MA, Erb HN. Comparison of two questionnaires to assess gastrointestinal toxicity in dogs and cats treated with chemotherapy. *Vet Comp Oncol* 2011;9:225-231.

Thompson HC, Cortes Y, Gannon K, Bailey D, Freer S. Esophageal foreign bodies in dogs: 34 cases (2004-2009). *J Vet Emerg Crit Care* 2012;22:253-261.

Fettig PK, Bailey DB, Gannon KM. Determination of strong ion gap in healthy dogs. *J Vet Emerg Crit Care* 2012;22:447-52.

Publications (cont.)

Regan RC, Kaplan MSW, Bailey DB. Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: results of a survey of veterinarians. *Vet Comp Oncol* 2013;11:287-295.

Waite A, Balkman C, Bailey D, Kiselow M, Flory A, Beaulieu BB, Lewis LD, McEntee M. Phase II study of oral docetaxel and cyclosporine in canine epithelial cancer. *Vet Comp Oncol* 2014;12:160-168.

Rassnick KM, Bailey DB, Malone EK, Flory AB, Kiselow MA, Intile JL. Tolerability of lomustine in combination with cyclophosphamide in dogs with cancer. *J Am Anim Hosp Assoc* 2014;50:167-173.

London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G. Impact of toceranib/piroxicam/cyclophosphamide maintenance therapy on outcome of dogs with appendicular osteosarcoma following amputation and carboplatin chemotherapy: A multi-institutional study. *PLoS One* 2015;10:e0124889.

Hess TA, Drinkhouse ME, Prey JD, Miller JM, Fettig AA, Carberry CA, Brenn SH, Bailey DB. Analysis of platinum content in compounded biodegradable carboplatin beads and retrospective analysis of tolerability when implanted in dogs with subcutaneous sarcomas: 29 cases (2011-2014). *J Am Vet Med Assoc* 2018;252:448-456.

Johannes CM, Rassnick KM, Bailey DB, Yanda NM, Regan R, Malone E, Intile JM, Kiselow M, Lucroy MD, Berger EP, Fox LF, Kamstock DA, LeBlanc CJ. Evaluation of factors associated with survival in dogs with lymphoma treated with prednisone. The Canine Lymphoma Steroid Only (CALYPSO) open-label prospective clinical trial: 69 cases (2016-2017). *J Am Vet Med Assoc*. In press.